Introduction
The HER2+ market focuses on therapies for cancers characterized by an overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2+ cancers, particularly in breast cancer but also in gastric, esophageal, and other solid tumors, have been associated with aggressive tumor growth and poor prognosis. However, HER2-targeted therapies, such as trastuzumab...
A diagnosis of HR+/HER2- breast cancer not only brings emotional and physical challenges but also significant economic burdens. Understanding these financial implications is crucial for patients and their families as they navigate their treatment journey. Here, we explore the various costs associated with HR+/HER2- breast cancer, the potential financial impact on patients, and strategies to...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian